Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofenac + metaxalone is a **combination medication** used to treat pain and muscle spasms associated with musculoskeletal conditions. The formulation combines **diclofenac potassium (50 mg)**, a nonsteroidal anti-inflammatory drug (NSAID), with **metaxalone (400 mg)**, a muscle relaxant. **Mechanism of Action:** - **Diclofenac** works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby blocking prostaglandin synthesis, which reduces pain, inflammation, and swelling - **Metaxalone** acts on the central nervous system, specifically on centers in the brain and spinal cord, to reduce muscle spasms and stiffness, though its exact mechanism remains unclear This combination provides dual action by targeting both the inflammatory component and muscular tension simultaneously, making it particularly effective for conditions like acute musculoskeletal pain, back pain, strains, sprains, muscle injuries, gout, joint pain, osteoarthritis, ankylosing spondylitis, and rheumatoid arthritis. The medication improves mobility and flexibility while providing quick relief from acute pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac + metaxalone.